Oral LSD Drug Hits Phase III Endpoints in Anxiety, Depression
(MedPage Today) -- DT120, an investigational orally disintegrating tablet (ODT) formulation of the psychedelic lysergide (LSD), met the primary endpoints in a pair of phase III trials for generalized anxiety disorder (GAD) and major depressive...